BWX Technologies and NorthStar Medical Radioisotopes sign supply agreement

BWX Technologies subsidiary BWXT Medical and NorthStar Medical Radioisotopes have signed a Master Services Agreement which will facilitate the production of actinium-225, a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues. The companies will work together to process and purify radium-226. The scope of the agreement also includes potential target design projects and exploration of opportunities to provide backup supply to each other’s customers. BWXT Medical will collaborate with NorthStar to streamline production processes, enhance safety protocols and innovate new methods of isotope generation. BWXT Medical recently submitted a Drug Master File for Actinium-225 API to the FDA.